Beth M. Jantzen's most recent trade in Applied Dna Sciences Inc was a trade of 98,039 Incentive Stock Option (right to buy) done . Disclosure was reported to the exchange on March 23, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Applied Dna Sciences Inc | Beth M. Jantzen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2023 | 98,039 | 98,039 | - | - | Incentive Stock Option (right to buy) | |
| Applied Dna Sciences Inc | Beth M. Jantzen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2023 | 91,667 | 91,739 (2%) | 2% | 0 | Common Stock | |
| Applied Dna Sciences Inc | Beth M. Jantzen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2023 | 1,961 | 1,961 | - | - | Non-Qualified Stock Option (right to buy) | |
| Applied Dna Sciences Inc | Beth M. Jantzen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2020 | 13,035 | 13,035 | - | - | Stock Option (right to buy) |